Furthermore, owing to RC48's bystander cytotoxic effect on tumor cells adjacent to HER2‐expressing cells, RC48 also exhibits antitumor activity in HER2‐negative or HER2‐low‐expressing patients. Here, ERBB2 is linked to neoplasm.